How Mayne Pharma's $888m Eagle landed

Mayne Pharma beat 60 bidders to seal the $888 million deal - code-named Project Eagle - to buy Teva and Allergan's drug portfolio.

The $22 billion a year disability insurance scheme is the biggest change to government welfare since Medicare.

Bankers are understood to be swarming over the next potential target in the vitamin industry, privately-owned PharmaCare.

Chris Roberts has run three of Australia's four great biotech success stories, will Clarity Pharmaceuticals be his next?

Few investors are more thrilled with Mayne Pharma's $888 million US generic drugs acquisition than Ophir Asset Management principal Andrew Mitchell.

Mayne Pharma has cemented its status as one of Australia's fastest growing companies with an $887 million acquisition in the US.

Change in the aged care sector will push operators to build scale and retirement villages to adopt more services.

Evolution Mining chairman Jake Klein says the company wants to stay a mid-tier to avoid the value destruction that has plagued the gold indu...

Some segments of UK-focused stocks will do well out of the Brexit. Glaxo is one of them.

Nature's Care sale process was launched on Tuesday, sources said, with an information memorandum sent to potential buyers.

My Saved Articles (0)